Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 02
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15
-1.46%
|
$4,455
$297.61 P/Share
|
|
Aug 01
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50
+4.65%
|
-
|
|
Jun 07
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,500
-46.22%
|
$1,197,000
$266.56 P/Share
|
|
Jun 07
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+31.61%
|
$378,000
$84.86 P/Share
|
|
May 06
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Open market or private sale
|
Direct |
2,500
-24.17%
|
$690,000
$276.55 P/Share
|
|
May 03
2021
|
Jean Luc Belingard Director |
SELL
Open market or private sale
|
Direct |
2,600
-14.31%
|
$699,400
$269.16 P/Share
|
|
May 03
2021
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+12.52%
|
$254,800
$98.49 P/Share
|
|
Apr 03
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
452
-4.19%
|
$113,904
$252.67 P/Share
|
|
Apr 03
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,010
+8.56%
|
-
|
|
Mar 30
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
812
-13.42%
|
$203,812
$251.88 P/Share
|
|
Mar 30
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
667
-11.76%
|
$167,417
$251.88 P/Share
|
|
Mar 27
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
687
-10.2%
|
$172,437
$251.58 P/Share
|
|
Mar 27
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+25.54%
|
-
|
|
Mar 27
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-15.98%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+26.33%
|
-
|
|
Mar 27
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-7.47%
|
$198,290
$251.58 P/Share
|
|
Mar 27
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
2,104
+16.59%
|
-
|
|
Mar 27
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-11.88%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+21.0%
|
-
|
|
Mar 27
2021
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-7.07%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Lance Berberian EVP, CIO & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+13.65%
|
-
|
|
Mar 27
2021
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
3,595
-8.76%
|
$902,345
$251.58 P/Share
|
|
Mar 27
2021
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Grant, award, or other acquisition
|
Direct |
8,042
+16.39%
|
-
|
|
Feb 18
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+37.95%
|
$355,224
$164.55 P/Share
|
|
Feb 18
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,317
-87.11%
|
$558,397
$241.51 P/Share
|
|
Feb 16
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
188
-2.1%
|
$44,556
$237.06 P/Share
|
|
Feb 16
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
208
-1.51%
|
$49,088
$236.33 P/Share
|
|
Feb 12
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
263
-11.93%
|
$62,594
$238.26 P/Share
|
|
Feb 12
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
867
+27.36%
|
-
|
|
Feb 12
2021
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
873
-2.23%
|
$207,774
$238.26 P/Share
|
|
Feb 12
2021
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,940
+6.59%
|
-
|
|
Feb 12
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
854
-4.2%
|
$203,252
$238.26 P/Share
|
|
Feb 12
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,870
+11.35%
|
-
|
|
Feb 12
2021
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
512
-0.78%
|
$121,856
$238.26 P/Share
|
|
Feb 12
2021
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
1,720
+2.54%
|
-
|
|
Feb 12
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
180
-1.06%
|
$42,840
$238.26 P/Share
|
|
Feb 12
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
581
+3.32%
|
-
|
|
Feb 12
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
142
-1.58%
|
$33,796
$238.26 P/Share
|
|
Feb 12
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
517
+5.43%
|
-
|
|
Feb 12
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-1.71%
|
$37,604
$238.26 P/Share
|
|
Feb 12
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
573
+5.85%
|
-
|
|
Feb 05
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
203
-4.66%
|
$45,675
$225.85 P/Share
|
|
Feb 05
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
109
-2.52%
|
$24,525
$225.85 P/Share
|
|
Feb 04
2021
|
Kerrii B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+4.73%
|
-
|
|
Feb 04
2021
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+45.97%
|
-
|
|
Feb 04
2021
|
Dwight Gary Gilliland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+12.74%
|
-
|
|
Feb 04
2021
|
Garheng Kong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+9.46%
|
-
|
|
Feb 04
2021
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+8.24%
|
-
|
|
Feb 04
2021
|
Richelle P Parham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+13.97%
|
-
|
|
Feb 04
2021
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
986
+13.66%
|
-
|